278 related articles for article (PubMed ID: 11273768)
21. Adenoviral-mediated skeletal muscle transcriptional targeting using chimeric tissue-specific promoters.
Frauli M; Ribault S; Neuville P; Augé F; Calenda V
Med Sci Monit; 2003 Feb; 9(2):BR78-84. PubMed ID: 12601283
[TBL] [Abstract][Full Text] [Related]
22. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
[TBL] [Abstract][Full Text] [Related]
23. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Stephens LC; Yu Y; Liu J; Fang B
Gene Ther; 2002 Oct; 9(20):1379-86. PubMed ID: 12365003
[TBL] [Abstract][Full Text] [Related]
24. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B
Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263
[TBL] [Abstract][Full Text] [Related]
25. A Renilla luciferase-Aequorea GFP (ruc-gfp) fusion gene construct permits real-time detection of promoter activation by exogenously administered mifepristone in vivo.
Yu YA; Szalay AA
Mol Genet Genomics; 2002 Oct; 268(2):169-78. PubMed ID: 12395191
[TBL] [Abstract][Full Text] [Related]
26. A versatile framework for the design of ligand-dependent, transgene-specific transcription factors.
Xu L; Zerby D; Huang Y; Ji H; Nyanguile OF; de los Angeles JE; Kadan MJ
Mol Ther; 2001 Feb; 3(2):262-73. PubMed ID: 11237684
[TBL] [Abstract][Full Text] [Related]
27. C-terminal deletion mutant p21(WAF1/CIP1) enhances E2F-1-mediated apoptosis in colon adenocarcinoma cells.
Elliott MJ; Stilwell A; Dong YB; Yang HL; Wong SL; Wrightson WR; Martin RC; McMasters KM
Cancer Gene Ther; 2002 May; 9(5):453-63. PubMed ID: 11961668
[TBL] [Abstract][Full Text] [Related]
28. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
29. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo.
Rivera AA; Wang M; Suzuki K; Uil TG; Krasnykh V; Curiel DT; Nettelbeck DM
Virology; 2004 Mar; 320(1):121-34. PubMed ID: 15003868
[TBL] [Abstract][Full Text] [Related]
30. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B
Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713
[TBL] [Abstract][Full Text] [Related]
31. Promoters influence the kinetics of transgene expression following adenovector gene delivery.
Chen P; Tian J; Kovesdi I; Bruder JT
J Gene Med; 2008 Feb; 10(2):123-31. PubMed ID: 18064718
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
[TBL] [Abstract][Full Text] [Related]
34. Expression of Gal4-dependent transgenes in cells of the mononuclear phagocyte system labeled with enhanced cyan fluorescent protein using Csf1r-Gal4VP16/UAS-ECFP double-transgenic mice.
Ovchinnikov DA; van Zuylen WJ; DeBats CE; Alexander KA; Kellie S; Hume DA
J Leukoc Biol; 2008 Feb; 83(2):430-3. PubMed ID: 17971498
[TBL] [Abstract][Full Text] [Related]
35. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
37. New complex Ad vectors incorporating both rtTA and tTS deliver tightly regulated transgene expression both in vitro and in vivo.
Rubinchik S; Woraratanadharm J; Yu H; Dong JY
Gene Ther; 2005 Mar; 12(6):504-11. PubMed ID: 15660114
[TBL] [Abstract][Full Text] [Related]
38. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
39. Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter.
Tanaka S; Iwai M; Harada Y; Morikawa T; Muramatsu A; Mori T; Okanoue T; Kashima K; Maruyama-Tabata H; Hirai H; Satoh E; Imanishi J; Mazda O
Cancer Gene Ther; 2000 Sep; 7(9):1241-50. PubMed ID: 11023196
[TBL] [Abstract][Full Text] [Related]
40. A novel system for mitigation of ectopic transgene expression induced by adenoviral vectors.
Reynolds PN; Holmes MD; Adachi Y; Kaliberova L; Curiel DT
Gene Ther; 2001 Aug; 8(16):1271-5. PubMed ID: 11509961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
